Related Experiment Video
Updated: Feb 10, 2026
Saturated Fatty Acids Induce Ceramide-associated Macrophage Cell Death
Published on: October 31, 2017
Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells
David Grünig1,2, Urs Duthaler1,2, Stephan Krähenbühl1,2,3
1Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland.
Abstract:
Impairment of hepatic fatty acid metabolism can lead to liver steatosis and injury. Testing drugs for interference with hepatic fatty acid metabolism is therefore important. To find out whether HepG2 cells are suitable for this purpose, we investigated the effect of three established fatty acid metabolism inhibitors and of three test compounds on triglyceride accumulation, palmitate metabolism, the acylcarnitine pool and dicarboxylic acid accumulation in the cell supernatant and on ApoB-100 excretion in HepG2 cells. The three established inhibitors [etomoxir, methylenecyclopropylacetic acid (MCPA), and 4-bromocrotonic acid (4-BCA)] depleted mitochondrial ATP at lower concentrations than cytotoxicity occurred, suggesting mitochondrial toxicity. They inhibited palmitate metabolism at similar or lower concentrations than ATP depletion, and 4-BCA was associated with cellular fat accumulation. They caused specific changes in the acylcarnitine pattern and etomoxir an increase of thapsic (C18 dicarboxylic) acid in the cell supernatant, and did not interfere with ApoB-100 excretion (marker of VLDL export). The three test compounds (amiodarone, tamoxifen, and the cannabinoid WIN 55,212-2) depleted the cellular ATP content at lower concentrations than cytotoxicity occurred. They all caused cellular fat accumulation and inhibited palmitate metabolism at similar or higher concentrations than ATP depletion. They suppressed medium-chain acylcarnitines in the cell supernatant and amiodarone and tamoxifen impaired thapsic acid production. Tamoxifen and WIN 55,212-2 decreased cellular ApoB-100 excretion. In conclusion, the established inhibitors of fatty acid metabolism caused the expected effects in HepG2 cells. HepG cells proved to be useful for the detection of drug-associated toxicities on hepatocellular fatty acid metabolism.
Insights
HepG2 cells are effective for detecting drug toxicity on liver fatty acid metabolism. This study shows these cells accurately reflect how drugs impact fat accumulation and metabolism, aiding drug safety testing.
Area of Science:
- Hepatology
- Biochemistry
- Pharmacology
Background:
- Impaired hepatic fatty acid metabolism is linked to liver steatosis and injury.
- Assessing drug interference with this pathway is crucial for drug development.
- HepG2 cells are a common model for liver studies, but their utility for fatty acid metabolism drug toxicity needs validation.
Purpose of the Study:
- To evaluate the suitability of HepG2 cells for detecting drug-induced alterations in hepatic fatty acid metabolism.
- To investigate the effects of known fatty acid metabolism inhibitors and test compounds on cellular processes in HepG2 cells.
Main Methods:
- HepG2 cells were treated with established inhibitors (etomoxir, MCPA, 4-BCA) and test compounds (amiodarone, tamoxifen, WIN 55,212-2).
- Assessed endpoints included triglyceride accumulation, palmitate metabolism, acylcarnitine profiles, dicarboxylic acid accumulation, and ApoB-100 excretion.
- Mitochondrial ATP levels and cytotoxicity were measured to correlate effects with toxicity.
Main Results:
- Established inhibitors demonstrated expected effects, including mitochondrial toxicity and altered palmitate metabolism.
- Test compounds induced cellular fat accumulation, inhibited palmitate metabolism, and affected acylcarnitine profiles.
- Specific compounds impacted thapsic acid production and ApoB-100 excretion, indicating interference with VLDL export.
Conclusions:
- HepG2 cells responded predictably to established fatty acid metabolism inhibitors.
- The cell model successfully detected drug-associated toxicities impacting hepatocellular fatty acid metabolism.
- HepG2 cells are validated as a useful tool for screening drug candidates for hepatic fatty acid metabolism interference.
Related Concept Videos
01:28Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
00:52What is Metabolism?
01:26Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
02:43Nucleic Acids
DNA and RNA
The two main types of nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). DNA is the genetic material in all living organisms, ranging from single-celled bacteria to multicellular mammals. It is in the nucleus of eukaryotes and in the organelles, chloroplasts, and mitochondria. In prokaryotes,...
02:43Nucleic acids
DNA and RNA
The two main types of nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). DNA is the genetic material in all living organisms, ranging from single-celled bacteria to multicellular mammals. It is in the nucleus of eukaryotes and in the organelles, chloroplasts, and mitochondria. In prokaryotes,...
03:42Amino acids